Rubicon Research Ltd

The Sensex gained a modest 0.75% on 2 Jun 2026, while Rubicon Research Ltd surged 9.95%, outperforming its Pharmaceuticals & Biotechnology sector by 10.56 percentage points. This sharp single-session advance, which pushed the stock to a new 52-week and all-time high of Rs 1285.7, signals a strong momentum continuation rather than a mere technical bounce.

Rubicon Research Ltd is rated Strong Buy by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 02 June 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Rubicon Research Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 2 June 2026, registering a robust 5.27% gain. The stock’s remarkable performance is underpinned by strong institutional participation, significant order flow, and a fresh 52-week high, signalling growing investor confidence amid a challenging market backdrop.

Surging to an all-time high of Rs 1258.2 on 2 Jun 2026, Rubicon Research Ltd has demonstrated remarkable price momentum, outpacing its sector and defying the broader market's subdued tone. This milestone caps a three-day rally that has delivered a 25.48% gain, underscoring the stock's robust technical backdrop amid a Sensex trading near its 52-week low.

With a decisive surge to Rs 1258.2 on 2 Jun 2026, Rubicon Research Ltd has reached a fresh 52-week and all-time high, propelled by a confluence of strong technical signals and sustained price momentum.

Extending its winning streak to three sessions, Rubicon Research Ltd surged 7.32% on 2 Jun 2026 to touch a fresh all-time high of Rs 1,238.5, significantly outpacing the Sensex which declined 0.33% on the same day.

Rubicon Research Ltd has recently been upgraded to an 'excellent' quality grade by MarketsMOJO, reflecting significant improvements in its business fundamentals. This upgrade, effective from 1 June 2026, highlights the company’s robust return metrics, prudent debt management, and consistent operational performance, positioning it favourably within the Pharmaceuticals & Biotechnology sector.

Rubicon Research Ltd., a small-cap pharmaceutical company with a market capitalisation of ₹18,586 crores, reported exceptional fourth-quarter results for FY26, with net profit surging 111.83% year-on-year to ₹76.79 crores. The strong performance, driven by robust revenue growth of 43.49% YoY to ₹513.92 crores, sent the stock soaring 16.24% on June 01, 2026, closing at ₹1,167.05 and nearly touching its 52-week high of ₹1,204.80.